About Exiqon
Exiqon is a Healthcare company based in Vedbæk (Denmark) founded in 1995, and was acquired by Qiagen in March 2016. LNA-based tools are developed for diagnostics and research applications. Exiqon has raised $22.9 million across 3 funding rounds from investors including Danske Bank, Qiagen and Teknoinvest. The company has 65 employees. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is EXIQON A/S.
Company details
Exiqon was founded in 1995 in Vedbaek, Denmark, within the biotechnology sector. LNA-based technologies are utilized across two units: Life Sciences, where research kits are produced, and Diagnostics, where biomarkers are detected and molecular tests are developed. Operations emphasize tools for scientific and clinical applications. Acquisition by Qiagen occurred in April 2016 for 103 million, integrating these capabilities into broader molecular diagnostics efforts.
- Headquarters Vedbæk, Denmark
- Employees 65
- Stage Acquired
- SectorsHealthcare
- Website exiqon.com
- Social LinkedIn Facebook
- Acquired by Qiagen (Mar 2016)
- Legal Name Exiqon A/S
- Total Equity Funding$22.9M (USD)
in 3 rounds
- Latest Funding Round$40M (USD), Debt – Conventional
Nov 2015
- InvestorsDanske Bank
& 2 more
- Employee Count65
- Acquired byQiagen
(Mar 2016)
Funding Insights of Exiqon
Exiqon has successfully raised a total of $22.9M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $40 million completed in November 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $22.9M
- Total Rounds 3
- Last Round Debt – Conventional — $40M
- First Round $3.2M
(Dec 2003)
- Investors Count 2
All 3 funding rounds of Exiqon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2015 | $40M | Debt – Conventional | – | – | – |
| Jun 2005 | $19.7M | Series B | – | – | |
| Dec 2003 | $3.2M | Series A | – | – | – |
3 investors in total: 3 institutional.
Investors in Exiqon
Exiqon has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Danske Bank, Qiagen and Teknoinvest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| teknoinvest.no | ||||
Financial services including banking and insurance are provided globally. | 1871 | danskebank.com | Copenhagen, Denmark | |
Products and reagents for molecular diagnostic assays are supplied. | 1984 | qiagen.com | Hilden, Germany |
Investor details for Exiqon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Exiqon
4 dated milestones of Exiqon across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Exiqon is founded.
- Funding First funding round of $3.2M.
- Funding Latest funding round, Debt – Conventional, of $40.0M.
- Exit Acquired by Qiagen.
Web traffic of Exiqon
Websites that share an audience with Exiqon (exiqon.com).
Websites whose visitors overlap most with Exiqon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| affymetrix.com | 100% | 1.1K | #9,164,392 | View details | |
promega.com | promega.com | 98% | #192,389 | – | |
microrna.org | microrna.org | 95% | – | ||
gelifesciences.com | gelifesciences.com | 91% | – | ||
| illumina.com | 90% | 672.7K | #61,793 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 26 similar websites and full traffic analytics for Exiqon
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 26 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Exiqon
Complete news archive for Exiqon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exiqon
Exiqon was founded in 1995 and raised its 1st funding round 8 years after it was founded.
Exiqon is headquartered in Vedbæk, Denmark.
Exiqon is a funded company, having raised a total of $22.9M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3.2M, raised on Dec 2003.
Exiqon has 65 employees.
Exiqon was founded in 1995 in Vedbaek, Denmark, within the biotechnology sector. LNA-based technologies are utilized across two units: Life Sciences, where research kits are produced, and Diagnostics, where biomarkers are detected and molecular tests are developed. Operations emphasize tools for scientific and clinical applications. Acquisition by Qiagen occurred in April 2016 for 103 million, integrating these capabilities into broader molecular diagnostics efforts.
Exiqon has 3 investors. Key investors include Danske Bank, Qiagen, and Teknoinvest.
Exiqon operates through Exiqon A/S.
Yes. Exiqon was acquired by Qiagen in March 2016.